TGFB1 and neoplasm: In preclinical studies, the combination of TGFβ and PD1/PD-L1 has resulted in modifying the immune evasion of the tumor cells by immune modulation from a decrease in recruitment of MDSC, T-reg, and NK cells to enhance the anti-tumor activity [33].